71 results
Acute promyelocytic leukemia (blood). Typical morphologic features are bilobed ("butterfly") nuclei with dispersed chromatin, subtle to
I see all of these ... promyelocytic #leukemia #APL ... #APML #Pathology ... #Hematology #Clinical ... #Smear
A 37-year-old woman initially presented with pancytopenia and found to have leukopenia (2.1 × 103/μL) with
promyelocytic leukemia (APL ... In addition to APL ... ) t(8;21), AML with ... #Clinical #Path ... Rods #AuerRods #APL
Auer Rods - Bone marrow aspiration revealed 5% blasts and 65% promyelocytes; many promyelocytes had prominent
#Clinical #Path ... #APL #AuerRods # ... AcutePromyelocyticLeukemia #Smear
Here are very large, immature myeloblasts with many nucleoli. A distincitve feature of these blasts is
myelogenous leukemia (AML ... #Clinical #Path ... BloodSmear #Blood #Smear ... Rods #AuerRods #AML
Leukemias Overview: ALL, CML, AML, APML, CLL

Acute leukemias > 20% blasts in the peripheral blood smear
, CML, AML, APML ... peripheral blood smear ... Score • CML -> AML ... • Peripheral smear ... : Blasts APML
Hypersegmented neutrophil in a case of acute myeloid leukemia.

Dysplastic neutrophils are typically hypolobated but can be
#neutrophils #AML ... #Clinical #Hematology ... #Pathology #Smear
Peripheral Blood shows a subset of atypical lymphocytes with hairy-like cytoplasmic projection.
#Clinical #Path #BloodSmear #Blood #Smear
#Clinical #Path ... BloodSmear #Blood #Smear
Antiphospholipid Syndrome (APS)
APS is a rare autoimmune disorder characterized by recurring blood clots resulting from antibodies
) APS is a rare ... Antiphospholipid antibodies (aPL ... at least: • 1 clinical ... 1 of the three aPLs ... presence of 1 clinical
Prolymphocytes

In our case, the patient has T-prolymphocytic leukemia (T-PLL) not Acute Myeloid Leukemia (AML).  🔬Tumor
Myeloid Leukemia (AML ... Prolymphocytes #Smear ... Pathology #Microscopy #Clinical
A normal peripheral blood smear indicates the appropriate appearance of red blood cells, with a zone
peripheral blood smear ... #Clinical #Path